drugset / Trial / NCT06109402

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

NCT06109402

Phase 2 Not yet recruiting 160 enrolled Shanghai Pulmonary Hospital, Shanghai, China
RandomizedParallel-groupOpen-labelTreatment

Summary

For resectable non-small cell lung cancer, neoadjuvant immunochemotherapy plus adjuvant immunotherapy or adjuvant immunochemotherapy is usually used in clinical practice. However, it is unclear whether therapeutic strategy is superior. This trial aims to compare the efficacy and safety of these two strategies.

Timeline

Start
2023-12-20
Primary completion
2030-11-01
Completion
2030-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Benmelstobart Monoclonal antibody
Subject Carboplatin Small molecule
Subject Paclitaxel Small molecule
Subject Pemetrexed Small molecule